Notably, after 43 days of treatment, significant reductions in AUC were observed in all groups receiving GLP-1 receptor agonists, indicating improved glycemic control ( Figure S4B , D , Method S3 )
The Triple Agonist: Retatrutide Retatrutide is frequently referred to in medical literature as a triple hormone receptor agonist or a triple incretin therapy
Procedures This study was a double-blind, randomized, placebo controlled trial where participants were placed into one of two groups randomly by blocks of two, controlling for sex and running time (clinicaltrials.gov identifier: NCT02172625, and S1 Checklist)
To address missing laboratory data (e.g., BMI, HbA1c, SBP, lipids, and UPCR), we included a distinct no measurement category for each variable in the propensity score model
First to market
Whats the Issue